Payers have put the squeeze on GlaxoSmithKline's top seller Advair, helping sink its sales and send company revenues tumbling. So GSK doesn't want to play with fire by hawking more high-priced meds. Instead, the company's identified a different path to growth, it said Wednesday--and the name of the game is volume.
GlaxoSmithKline will have some questions to answer this week after reporting its first quarterly results with Novartis' former vaccines stable. The company's vaccines unit saw its operating profit plummet and operating margin decline after folding in the Swiss drugmaker's business.
GlaxoSmithKline's respiratory woes continued in Q1, with stateside sales of aging blockbuster Advair sinking 22%. The company has pricing pressure to thank for that slide.
About that ViiV Healthcare spinoff GlaxoSmithKline's been looking at--it's not happening, the pharma giant says.
GlaxoSmithKline is facing sluggish sales in the U.S. and revenue growth that falls behind that of its Big Pharma rivals, not to mention scrutiny for CEO Andrew Witty. So Philip Hampton will have his work cut out for him as he steps into his new role as the company's chairman and attempts to revive the company's lagging fortunes.
Close to 5 years after GlaxoSmithKline signed on to collaborate with the San Raffaele Telethon Institute for Gene Therapy in Italy, the partners have stepped up with a European application to start marketing a gene therapy for extraordinarily rare cases of immune deficiency triggered by ADA-SCID. And its delivery into regulatory hands comes as the gene therapy field has been recoiling from some notable setbacks that have begun to cloud what has been a bullish sector in biotech.
Analysts are suggesting that GlaxoSmithKline is thinking hard about scrapping a plan to reward investors by paying them about £4 billion and instead use money from its deals with Novartis to prop up its dividend, Reuters reports.
GlaxoSmithKline CEO Andrew Witty recently said slow-starting respiratory newcomer Breo was finally gaining some market traction. And now, it has a new asthma indication the company hopes can help speed things along.
GlaxoSmithKline has shone in a ranking of the social media savvy of the 100 largest publicly traded firms in the United Kingdom. The Big Pharma ranked second on the list, an outcome that suggests at least some drugmakers compare favorably to their peers in other industries.
GlaxoSmithKline needed to jump-start sluggish sales of its respiratory newcomers Breo and Anoro after early uptake fell short of expectations. Now a targeted DTC push may be charging up sales.